Skye生物科学许可Halozyme的科技开发高剂量亚丁基肥胖药物Nimacimab, 目标是2026年中期第2B阶段试验。 Skye Bioscience licenses Halozyme’s tech to develop higher-dose subcutaneous obesity drug nimacimab, targeting a mid-2026 Phase 2b trial.

斯凯生物科学公司已经授权Halozyme的ENHANZE技术开发高剂量,皮下治疗肥胖症的尼马西马布配方,并计划在2026年中期进行第二阶段b试验. Skye Bioscience has licensed Halozyme’s ENHANZE technology to develop higher-dose, subcutaneous formulations of nimacimab for obesity, with plans for a Phase 2b trial in mid-2026. 全球协议包括里程碑付款和Halozyme的中位数版权使用费。 The global deal includes milestone payments and mid-single digit royalties for Halozyme. Skye旨在探索与GLP-1药物的结合,以加强各种治疗方案。 Skye aims to explore combinations with GLP-1 drugs to enhance treatment options. 斯凯的股价在市场前升至0.97美元, 增长11.44%, 而Halozyme则上0.21%, 达到70.46美元. The news boosted Skye’s pre-market shares to $0.97, up 11.44%, while Halozyme rose 0.21% to $70.46.